David J Salant

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4246972/publications.pdf

Version: 2024-02-01

138	12,517	34105 52	24258 110
papers	citations	h-index	g-index

161	161	161	7713
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	M-Type Phospholipase A₂Receptor as Target Antigen in Idiopathic Membranous Nephropathy. New England Journal of Medicine, 2009, 361, 11-21.	27.0	1,870
2	Thrombospondin Type-1 Domain-Containing 7A in Idiopathic Membranous Nephropathy. New England Journal of Medicine, 2014, 371, 2277-2287.	27.0	729
3	Methylation determines fibroblast activation and fibrogenesis in the kidney. Nature Medicine, 2010, 16, 544-550.	30.7	537
4	RANTES and Monocyte Chemoattractant Proteinâ€“1 (MCP-1) Play an Important Role in the Inflammatory Phase of Crescentic Nephritis, but Only MCP-1 Is Involved in Crescent Formation and Interstitial Fibrosis. Journal of Experimental Medicine, 1997, 185, 1371-1380.	8.5	462
5	Rituximab-Induced Depletion of Anti-PLA2R Autoantibodies Predicts Response in Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2011, 22, 1543-1550.	6.1	403
6	Anti-Phospholipase A2 Receptor Antibody in Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2011, 22, 1137-1143.	6.1	366
7	Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease). Journal of the American Society of Nephrology: JASN, 2005, 16, 1392-1403.	6.1	354
8	Experimental glomerulonephritis in the isolated perfused rat kidney.. Journal of Clinical Investigation, 1978, 62, 1275-1287.	8.2	351
9	In situ immune complex formation and glomerular injury. Kidney International, 1980, 17, 1-13.	5.2	328
10	Anti-Phospholipase A2 Receptor Antibodies Correlate with Clinical Status in Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1286-1291.	4.5	320
11	A new role for complement in experimental membranous nephropathy in rats.. Journal of Clinical Investigation, 1980, 66, 1339-1350.	8.2	280
12	New Approaches to the Treatment of Dense Deposit Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 2447-2456.	6.1	231
13	Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nature Medicine, 2011, 17, 1242-1250.	30.7	204
14	Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. Journal of Clinical Investigation, 2004, 114, 679-688.	8.2	185
15	Cloning of rat nephrin: Expression in developing glomeruli and in proteinuric states. Kidney International, 2000, 57, 1949-1961.	5.2	176
16	Membranous nephropathy: recent travels and new roads ahead. Kidney International, 2010, 77, 765-770.	5.2	175
17	An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domainâ€“Containing 7Aâ€“Specific Antibodies in Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2017, 28, 520-531.	6.1	172
18	Complement-induced glomerular epithelial cell injury. Role of the membrane attack complex in rat membranous nephropathy.. Journal of Clinical Investigation, 1986, 77, 1096-1107.	8.2	159

#	Article	IF	Citations
19	Experimental Membranous Glomerulonephritis in Rats. Journal of Clinical Investigation, 1980, 66, 71-81.	8.2	157
20	Nephritogenic mAb 5-1-6 is directed at the extracellular domain of rat nephrin. Journal of Clinical Investigation, 1999, 104, 1559-1566.	8.2	154
21	Rapamycin Ameliorates Proteinuria-Associated Tubulointerstitial Inflammation and Fibrosis in Experimental Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2005, 16, 2063-2072.	6.1	146
22	Targeted deletion of CX3CR1 reveals a role for fractalkine in cardiac allograft rejection. Journal of Clinical Investigation, 2001, 108, 679-688.	8.2	145
23	Lack of chemokine receptor CCR1 enhances Th1 responses and glomerular injury during nephrotoxic nephritis. Journal of Clinical Investigation, 1999, 104, 1549-1557.	8.2	145
24	Membranous nephropathy: from models to man. Journal of Clinical Investigation, 2014, 124, 2307-2314.	8.2	141
25	Role of abnormally high transmural pressure in the permselectivity defect of glomerular capillary wall: a study in early passive Heymann nephritis.. Circulation Research, 1987, 61, 531-538.	4.5	128
26	[38] Experimental glomerulonephritis. Methods in Enzymology, 1988, 162, 421-461.	1.0	123
27	Membranous Nephropathy: A Journey From Bench to Bedside. American Journal of Kidney Diseases, 2016, 68, 138-147.	1.9	115
28	Association of Pathological Fibrosis With Renal Survival Using Deep Neural Networks. Kidney International Reports, 2018, 3, 464-475.	0.8	114
29	Experimental membranous nephropathy redux. American Journal of Physiology - Renal Physiology, 2005, 289, F660-F671.	2.7	110
30	Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. Journal of Clinical Investigation, 2004, 114, 679-688.	8.2	104
31	Podocyte slit-diaphragm protein nephrin is linked to the actin cytoskeleton. American Journal of Physiology - Renal Physiology, 2002, 282, F585-F591.	2.7	101
32	Nephrin Dissociates from Actin, and Its Expression Is Reduced in Early Experimental Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2002, 13, 946-956.	6.1	98
33	Heymann nephritis: Mechanisms of renal injury. Kidney International, 1989, 35, 976-984.	5.2	97
34	Insights into Glomerular Filtration and Albuminuria. New England Journal of Medicine, 2021, 384, 1437-1446.	27.0	96
35	Anti-Fx1A produces complement-dependent cytotoxicity of glomerular epithelial cells. Kidney International, 1988, 34, 43-52.	5.2	95
36	Role of the terminal complement pathway in experimental membranous nephropathy in the rabbit.. Journal of Clinical Investigation, 1983, 72, 1948-1957.	8.2	95

#	Article	IF	Citations
37	Nephrin and podocin dissociate at the onset of proteinuria in experimental membranous nephropathy. Kidney International, 2005, 67, 2239-2253.	5.2	94
38	Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1â€“associated membranous nephropathy. Journal of Clinical Investigation, 2021, 131, .	8.2	94
39	Role of MCP-1 and RANTES in inflammation and progression to fibrosis during murine crescentic nephritis. Journal of Leukocyte Biology, 1997, 62, 676-680.	3.3	92
40	Crk1/2-dependent signaling is necessary for podocyte foot process spreading in mouse models of glomerular disease. Journal of Clinical Investigation, 2012, 122, 674-692.	8.2	92
41	The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia. Circulation, 2016, 134, 61-72.	1.6	89
42	Lysophosphatidic acid and renal fibrosis. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2008, 1781, 582-587.	2.4	78
43	Acute nephrotoxic serum nephritis in complement knockout mice: relative roles of the classical and alternate pathways in neutrophil recruitment and proteinuria. Nephrology Dialysis Transplantation, 1998, 13, 2799-2803.	0.7	77
44	Complement-mediated injury reversibly disrupts glomerular epithelial cell actin microfilaments and focal adhesions. Kidney International, 1999, 55, 1763-1775.	5.2	76
45	IL-15, a survival factor for kidney epithelial cells, counteracts apoptosis and inflammation during nephritis. Journal of Clinical Investigation, 2002, 109, 951-960.	8.2	70
46	Essential role of Gas6 for glomerular injury in nephrotoxic nephritis. Journal of Clinical Investigation, 2002, 110, 239-246.	8.2	70
47	Decay-Accelerating Factor Confers Protection Against Complement-Mediated Podocyte Injury in Acute Nephrotoxic Nephritis. Laboratory Investigation, 2002, 82, 563-569.	3.7	69
48	Evaluation of Anti-PLA2R1 as Measured by a Novel ELISA in Patients With Idiopathic Membranous Nephropathy. American Journal of Clinical Pathology, 2014, 142, 29-34.	0.7	67
49	Membranous Nephropathy Associated With IgG4-Related Disease. American Journal of Kidney Diseases, 2011, 58, 272-275.	1.9	64
50	Immunopathogenesis of crescentic glomerulonephritis and lung purpura. Kidney International, 1987, 32, 408-425.	5.2	63
51	Complement mediates nephrin redistribution and actin dissociation in experimental membranous nephropathy. Kidney International, 2003, 64, 2072-2078.	5.2	60
52	Role of terminal complement pathway in the heterologous phase of antiglomerular basement membrane nephritis. Kidney International, 1985, 27, 643-651.	5.2	58
53	LDL Receptor-Related Protein 2 (Megalin) as a Target Antigen in Human Kidney Anti-Brush Border Antibody Disease. Journal of the American Society of Nephrology: JASN, 2018, 29, 644-653.	6.1	57
54	Antiâ€“Phospholipase A2 Receptor Antibodies and Malignancy in Membranous Nephropathy. American Journal of Kidney Diseases, 2013, 62, 1223-1225.	1.9	55

#	Article	IF	Citations
55	Inhibitory Effects of Robo2 on Nephrin: A Crosstalk between Positive and Negative Signals Regulating Podocyte Structure. Cell Reports, 2012, 2, 52-61.	6.4	53
56	Inhibition of Complement Regulation Is Key to the Pathogenesis of Active Heymann Nephritis. Journal of Experimental Medicine, 1998, 188, 1353-1358.	8.5	52
57	Cytosolic calcium and protein kinase C reduce complement-mediated glomerular epithelial injury. Kidney International, 1990, 38, 803-811.	5.2	51
58	Inhibition of Histone Deacetylase Activates Side Population Cells in Kidney and Partially Reverses Chronic Renal Injury. Stem Cells, 2007, 25, 2469-2475.	3.2	51
59	Intercellular adhesion molecule-1 deficiency prolongs survival and protects against the development of pulmonary inflammation during murine lupus.. Journal of Clinical Investigation, 1997, 100, 963-971.	8.2	51
60	Mediation of proteinuria in membranous nephropathy due to a planted glomerular antigen. Kidney International, 1983, 23, 807-815.	5.2	50
61	Aminopeptidase A: A nephritogenic target antigen of nephrotoxic serum. Kidney International, 2001, 59, 601-613.	5.2	49
62	Podocyte-specific deletion of signal transducer and activator of transcription 3 attenuates nephrotoxic serumâ€“induced glomerulonephritis. Kidney International, 2013, 84, 950-961.	5.2	48
63	Essential role of Gas6 for glomerular injury in nephrotoxic nephritis. Journal of Clinical Investigation, 2002, 110, 239-246.	8.2	48
64	Influence of antigen distribution on the mediation of immunological glomerular injury. Kidney International, 1985, 27, 938-950.	5.2	47
65	Blockade of the Kinin B1 Receptor Ameloriates Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2010, 21, 1157-1164.	6.1	47
66	IL-6 Trans-Signaling Drives Murine Crescentic GN. Journal of the American Society of Nephrology: JASN, 2016, 27, 132-142.	6.1	45
67	Respective Roles of Decay-Accelerating Factor and CD59 in Circumventing Glomerular Injury in Acute Nephrotoxic Serum Nephritis. Journal of Immunology, 2004, 172, 2636-2642.	0.8	41
68	IgG4-Related Disease Is Not Associated with Antibody to the Phospholipase A2 Receptor. International Journal of Rheumatology, 2012, 2012, 1-6.	1.6	39
69	Genetic Variants in Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2013, 24, 525-528.	6.1	38
70	Anuric Renal Failure Precipitated by Indomethacin and Triamterene. Nephron, 1985, 40, 216-218.	1.8	37
71	Slit diaphragm-reactive nephritogenic MAb 5-1-6 alters expression of ZO-1 in rat podocytes. American Journal of Physiology - Renal Physiology, 1997, 273, F984-F993.	2.7	37
72	IL-15, a survival factor for kidney epithelial cells, counteracts apoptosis and inflammation during nephritis. Journal of Clinical Investigation, 2002, 109, 951-960.	8.2	35

#	Article	IF	Citations
73	Comparative study of in situ immune deposit formation in active and passive Heymann nephritis. Kidney International, 1983, 23, 498-505.	5.2	34
74	SLIT2/ROBO2 signaling pathway inhibits nonmuscle myosin IIA activity and destabilizes kidney podocyte adhesion. JCI Insight, 2016, 1, e86934.	5.0	34
75	The structural biology of glomerular epithelial cells in proteinuric diseases. Current Opinion in Nephrology and Hypertension, 1994, 3, 569-574.	2.0	32
76	Retinoic acid improves nephrotoxic serumâ€“induced glomerulonephritis through activation of podocyte retinoic acid receptor Î±. Kidney International, 2017, 92, 1444-1457.	5.2	32
77	Fish oil has protective and therapeutic effects on proteinuria in passive Heymann nephritis. Kidney International, 1993, 43, 359-368.	5.2	31
78	Shp2 Associates with and Enhances Nephrin Tyrosine Phosphorylation and Is Necessary for Foot Process Spreading in Mouse Models of Podocyte Injury. Molecular and Cellular Biology, 2016, 36, 596-614.	2.3	30
79	The effect of VH residues 6 and 23 on IgG3 cryoprecipitation and glomerular deposition. European Journal of Immunology, 1995, 25, 279-284.	2.9	29
80	SRY-Related HMG Box 9 Regulates the Expression of Col4a2 through Transactivating Its Enhancer Element in Mesangial Cells. American Journal of Pathology, 2007, 170, 1854-1864.	3.8	29
81	Altered glomerular permeability induced by F(abâ€²)2 and Fabâ€² antibodies to rat renal tubular epithelial antigen. Kidney International, 1982, 21, 36-43.	5.2	28
82	The fate of Notch-deficient nephrogenic progenitor cells during metanephric kidney development. Kidney International, 2011, 79, 1099-1112.	5.2	28
83	Unmet challenges in membranous nephropathy. Current Opinion in Nephrology and Hypertension, 2019, 28, 70-76.	2.0	27
84	Expression of type I collagen mRNA in glomeruli of rats with passive Heymann nephritis. Kidney International, 1993, 43, 121-127.	5.2	26
85	Pregnancy in a Patient With Primary Membranous Nephropathy and Circulating Anti-PLA2R Antibodies: A Case Report. American Journal of Kidney Diseases, 2016, 67, 775-778.	1.9	26
86	Activation of fibroblastic reticular cells in kidney lymph node during crescentic glomerulonephritis. Kidney International, 2019, 95, 310-320.	5.2	26
87	Effect of antibody charge and concentration on deposition of antibody to glomerular basement membrane. Kidney International, 1984, 26, 397-403.	5.2	25
88	KrÃ¼ppel-like factor 4 is a negative regulator of STAT3-induced glomerular epithelial cell proliferation. JCI Insight, 2018, 3, .	5.0	24
89	Goodpasture's Disease â€" New Secrets Revealed. New England Journal of Medicine, 2010, 363, 388-391.	27.0	22
90	Targeting Complement C5 in Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2011, 22, 7-9.	6.1	22

#	Article	IF	Citations
91	Podocyte Expression of B7-1/CD80. Journal of the American Society of Nephrology: JASN, 2016, 27, 963-965.	6.1	21
92	Thrombotic Microangiopathy: A Multidisciplinary TeamÂApproach. American Journal of Kidney Diseases, 2017, 70, 715-721.	1.9	20
93	A Case of Atypical Light Chain Deposition Diseaseâ€"Diagnosis and Treatment. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 858-867.	4.5	18
94	Loss of Zeb2 in mesenchyme-derived nephrons causes primary glomerulocystic disease. Kidney International, 2016, 90, 1262-1273.	5.2	17
95	Treatment of Membranous Lupus Nephritis. Journal of the American Society of Nephrology: JASN, 2009, 20, 690-691.	6.1	15
96	Noninvasive Assessment of Antenatal Hydronephrosis in Mice Reveals a Critical Role for Robo2 in Maintaining Anti-Reflux Mechanism. PLoS ONE, 2011, 6, e24763.	2.5	14
97	Coexistence of ANCA-associated glomerulonephritis and anti-phospholipase A2 receptor antibody-positive membranous nephropathy. CKJ: Clinical Kidney Journal, 2012, 5, 162-165.	2.9	14
98	Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1138-1140.	4.5	14
99	Effect of diet, age and sex on the renal response to immune injury in the rat. Kidney International, 1988, 33, 561-570.	5.2	13
100	In Search of the Elusive Membranous Nephropathy Antigen. Nephron Physiology, 2009, 112, p11-p12.	1.2	13
101	Charge selective properties of the glomerular capillary wall influence antibody binding in rat membranous nephropathy. Clinical Immunology and Immunopathology, 1986, 39, 131-138.	2.0	12
102	Quantitation of exogenous and endogenous components of glomerular immune deposits. Kidney International, 1986, 30, 255-263.	5.2	12
103	Antibody, antigen, and glomerular capillary wall charge interactions: Influence of antigen location on in situ immune complex formation. Kidney International, 1986, 29, 649-657.	5.2	12
104	ANCA: Fuel for the fire or the spark that ignites the flame?. Kidney International, 1999, 55, 1125-1127.	5.2	12
105	ABIN1 Determines Severity of Glomerulonephritis via Activation of Intrinsic Glomerular Inflammation. American Journal of Pathology, 2017, 187, 2799-2810.	3.8	12
106	Podocyte-specific KLF4 is required to maintain parietal epithelial cell quiescence in the kidney. Science Advances, 2021, 7, eabg6600.	10.3	12
107	Aln-CC5, an Investigational RNAi Therapeutic Targeting C5 for Complement Inhibition. Blood, 2014, 124, 1606-1606.	1.4	12
108	Glomerular epithelial cell products stimulate mesangial cell proliferation in culture. Kidney International, 1997, 52, 733-741.	5.2	11

#	Article	IF	Citations
109	Glomerular and Tubulointerstitial Diseases. Primary Care - Clinics in Office Practice, 2008, 35, 265-296.	1.6	11
110	Role of nephrin in proteinuric renal diseases. Seminars in Immunopathology, 2003, 24, 423-439.	4.0	10
111	Does Epitope Spreading Influence Responsiveness to Rituximab in PLA2R-Associated Membranous Nephropathy?. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1122-1124.	4.5	10
112	Loss of Roundabout Guidance Receptor 2 (Robo2) in Podocytes Protects Adult Mice from Glomerular Injury by Maintaining Podocyte Foot ProcessÂStructure. American Journal of Pathology, 2020, 190, 799-816.	3.8	10
113	Coexistence of ANCA-associated glomerulonephritis and anti-phospholipase A2 receptor antibody-positive membranous nephropathy. CKJ: Clinical Kidney Journal, 2012, 5, 162-165.	2.9	10
114	Case 41-1990. New England Journal of Medicine, 1990, 323, 1050-1061.	27.0	8
115	Effects of omega-3 fatty acids on complement-mediated glomerular epithelial cell injury. Kidney International, 1996, 50, 1863-1871.	5.2	7
116	Treatment of acute interstitial nephritis. Renal Failure, 1998, 20, 829-838.	2.1	7
117	Neutrophil exocytosis induces podocyte cytoskeletal reorganization and proteinuria in experimental glomerulonephritis. American Journal of Physiology - Renal Physiology, 2018, 315, F595-F606.	2.7	7
118	Advancing Nephrology. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 319-327.	4.5	7
119	Analgesic abuse and microvascular changes. American Heart Journal, 1978, 95, 268-269.	2.7	6
120	Visceral Glomerular Epithelial Cell DNA Synthesis in Experimental and Human Membranous Disease. Nephron Experimental Nephrology, 1998, 6, 352-358.	2.2	6
121	Glomerular Disease Workshop. Journal of the American Society of Nephrology: JASN, 2005, 16, 3472-3476.	6.1	6
122	Refining Our Understanding of the PLA2R-Antibody Response in Primary Membranous Nephropathy: Looking Forward, Looking Back. Journal of the American Society of Nephrology: JASN, 2020, 31, 8-11.	6.1	6
123	Immune complex glomerulonephritis. Clinical and Experimental Nephrology, 1998, 2, 271-275.	1.6	4
124	Towards minimally-invasive, quantitative assessment of chronic kidney disease using optical spectroscopy. Scientific Reports, 2019, 9, 7168.	3.3	4
125	Complement Deficiencies Result in Surrogate Pathways of Complement Activation in Novel Polygenic Lupus-like Models of Kidney Injury. Journal of Immunology, 2020, 204, 2627-2640.	0.8	4
126	PODO: Trial Design: Phase 2 Study of PF-06730512 in Focal Segmental Glomerulosclerosis. Kidney International Reports, 2021, 6, 1629-1633.	0.8	4

#	Article	IF	Citations
127	An outline of essential topics in glomerular pathophysiology, diagnosis, and treatment for nephrology trainees. American Journal of Kidney Diseases, 2003, 42, 395-418.	1.9	3
128	Concurrent Presentation of Thrombotic Thrombocytopenic Purpura and Membranous Nephropathy. Kidney International Reports, 2018, 3, 476-481.	0.8	3
129	Management of glomerular diseases of primary and secondary origin. Current Opinion in Nephrology and Hypertension, 1992, 1, 124-132.	2.0	2
130	Intravenous methylprednisolone or plasma exchange for adjunctive therapy of severe renal vasculitis?. Nature Clinical Practice Nephrology, 2008, 4, 14-15.	2.0	2
131	Introduction: Complement-Mediated Kidney Diseases. Seminars in Nephrology, 2013, 33, 477-478.	1.6	2
132	Deep pockets are not necessarily a good thing in membranous nephropathy: evidence for a modifier allele. Kidney International, 2018, 94, 855-857.	5.2	2
133	The nephritogenic immune response. Current Opinion in Nephrology and Hypertension, 1994, 3, 318-328.	2.0	1
134	Renal immunology and pathology. Current Opinion in Nephrology and Hypertension, 1997, 6, 257-258.	2.0	0
135	Renal immunology and pathology. Current Opinion in Nephrology and Hypertension, 1998, 7, 279-280.	2.0	0
136	Authors' reply:. American Journal of Kidney Diseases, 2000, 36, 217-219.	1.9	0
137	TD-02â€...Kidney tissue damage in mice with single and combined abnormalities in complement, interferon and apoptotic cell clearance. , 2018, , .		0
138	Nephritogenic mAb 5-1-6 is directed at the extracellular domain of rat nephrin. Journal of Clinical Investigation, 2000, 105, 125-125.	8.2	0